---
id: malaria-treatment-by-species_094
category: organisms
tags: [malaria-treatment, artemisinin, atovaquone-proguanil, chloroquine, primaquine, G6PD]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Malaria: Treatment by Species (Uncomplicated)

**Q:** What are the treatment regimens for uncomplicated malaria by Plasmodium species, including chloroquine-resistant vs chloroquine-sensitive regions?

**A:**

## OVERVIEW

**Key Principles:**
- **Species identification determines treatment**
- **Geographic origin determines resistance patterns**
- **Chloroquine resistance:** Widespread *P. falciparum* (except Haiti, Central America west of Panama Canal, Middle East)
- **Artemisinin resistance:** Emerging *P. falciparum* (Southeast Asia - Cambodia, Thailand, Myanmar)

---

## CHLOROQUINE RESISTANCE MAP

**Chloroquine-Sensitive *P. falciparum*:**
- **Haiti, Dominican Republic**
- **Central America west of Panama Canal** (Guatemala, El Salvador, Honduras)
- **Middle East** (except Saudi Arabia/Yemen border)

**Chloroquine-Resistant *P. falciparum*:**
- **Sub-Saharan Africa** (ALL regions)
- **Southeast Asia, South Asia**
- **Latin America** (except above)
- **Oceania**

**Key Point:** **Chloroquine-resistant *P. falciparum* = worldwide** (except Haiti, Central America west of Panama Canal, Middle East)

---

## 1. *PLASMODIUM FALCIPARUM* (UNCOMPLICATED)

---

### **A. Chloroquine-Resistant *P. falciparum* (MOST Cases):**

**First-Line Options (Choose One):**

---

#### **Option 1: Artemisinin-Based Combination Therapy (ACT) - WHO Recommended:**

| **ACT Regimen** | **Dosing** | **Duration** | **Availability** |
|-----------------|------------|--------------|------------------|
| **Artemether-lumefantrine (Coartem)** | **4 tablets PO BID** (with fatty food) | **3 days** | **FDA-approved** (US) |
| **Artesunate-amodiaquine** | 4 mg/kg artesunate + 10 mg/kg amodiaquine PO daily | 3 days | Africa, not FDA-approved |
| **Artesunate-mefloquine** | 4 mg/kg artesunate + 8 mg/kg mefloquine PO daily | 3 days | Southeast Asia, not FDA-approved |
| **Dihydroartemisinin-piperaquine** | 4 mg/kg DHA + 18 mg/kg piperaquine PO daily | 3 days | Southeast Asia, not FDA-approved |

**Key Point:** **Artemether-lumefantrine (Coartem) = FDA-approved ACT** in US

---

#### **Option 2: Atovaquone-Proguanil (Malarone):**

**Dosing:**
- **4 tablets (250/100 mg) PO daily** (with food or milky drink)

**Duration:** **3 days**

**Advantages:**
- **Well-tolerated**
- **Once-daily dosing**

**Limitations:**
- **Expensive** (~$200 for treatment course)
- **Not for severe malaria**

---

#### **Option 3: Quinine + Doxycycline (or Clindamycin):**

**Dosing:**
- **Quinine sulfate** 650 mg PO TID x **3 days** (or **7 days** if from Southeast Asia)
  **PLUS**
- **Doxycycline** 100 mg PO BID x **7 days**
  **OR Clindamycin** 20 mg/kg/day PO divided TID x **7 days** (if pregnant or child)

**Advantages:**
- **Widely available**

**Limitations:**
- **Poor tolerability** (cinchonism: tinnitus, headache, nausea, visual changes)
- **Hypoglycemia risk** (quinine-induced insulin release)
- **Longer duration** (7 days)

---

#### **Option 4: Mefloquine (Lariam):**

**Dosing:**
- **750 mg PO x1, then 500 mg PO 6-12 hours later**

**Duration:** **1-2 doses (single day)**

**Advantages:**
- **Short course**

**Limitations:**
- **Neuropsychiatric side effects** (anxiety, depression, psychosis, seizures)
- **Mefloquine resistance** (Southeast Asia)
- **Contraindicated:** Psychiatric history, seizure disorder, cardiac conduction abnormalities

**Key Point:** **Avoid mefloquine** if psychiatric history (neuropsychiatric side effects)

---

**Preferred Regimens Summary (Chloroquine-Resistant *P. falciparum*):**
1. **Artemether-lumefantrine (Coartem)** - 4 tablets PO BID x 3 days (FDA-approved)
2. **Atovaquone-proguanil (Malarone)** - 4 tablets PO daily x 3 days
3. **Quinine + doxycycline** - Quinine 650 mg PO TID x 3-7 days + Doxycycline 100 mg PO BID x 7 days

---

### **B. Chloroquine-Sensitive *P. falciparum* (RARE - Haiti, Central America west of Panama Canal, Middle East):**

**Treatment:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Chloroquine phosphate** | **600 mg base (1000 mg salt) PO x1**<br>Then **300 mg base (500 mg salt) PO at 6h, 24h, 48h** |

**Total Dose:** **1500 mg base (2500 mg salt) over 3 days**

**Key Point:** **Chloroquine effective ONLY if from Haiti, Central America west of Panama Canal, or Middle East**

---

## 2. *PLASMODIUM VIVAX* OR *PLASMODIUM OVALE* (RELAPSING)

**Two-Phase Treatment:**
1. **Blood-stage schizonticide** (kill blood-stage parasites)
2. **Hypnozoitocide** (kill dormant liver stage → prevent relapses)

---

### **Phase 1: Blood-Stage Treatment**

---

#### **Chloroquine-Sensitive *P. vivax* (MOST Regions):**

**Treatment:**
- **Chloroquine phosphate** 600 mg base PO x1, then 300 mg base PO at 6h, 24h, 48h

**Chloroquine-Resistant *P. vivax* (Papua New Guinea, Indonesia):**

**Treatment (Choose One):**
- **Atovaquone-proguanil** 4 tablets PO daily x 3 days
- **Artemether-lumefantrine** 4 tablets PO BID x 3 days
- **Quinine + doxycycline** (as above)

---

### **Phase 2: Hypnozoitocide (Prevent Relapses)**

**ESSENTIAL for *P. vivax* and *P. ovale*** (have dormant liver stage)

---

#### **Primaquine (First-Line):**

**Dosing:**
- **30 mg base (52.6 mg salt) PO daily x 14 days**

**Efficacy:**
- **Prevents relapses** (eradicates hypnozoites)

**Key Point:** **G6PD testing MANDATORY** before primaquine (risk of hemolysis)

---

**G6PD Deficiency:**

**If G6PD Deficient:**
- **Mild deficiency (>10% activity):** Primaquine 45 mg base PO weekly x 8 weeks (alternative)
- **Severe deficiency (<10% activity):** **DO NOT give primaquine** (risk of severe hemolysis)

**If G6PD Normal:**
- **Primaquine** 30 mg base PO daily x 14 days

---

#### **Tafenoquine (FDA-Approved 2018 - Alternative):**

**Dosing:**
- **300 mg PO x 1 dose** (single dose)

**Advantages:**
- **Single dose** (vs 14 days primaquine)
- **Better compliance**

**Limitations:**
- **G6PD testing MANDATORY** (same hemolysis risk as primaquine)
- **Not for G6PD deficiency**
- **Not for pregnancy, breastfeeding**

**Key Point:** **Tafenoquine = single-dose alternative to primaquine** (but G6PD testing still required)

---

**Treatment Summary (*P. vivax*/*P. ovale*):**
1. **Chloroquine** 600 mg base → 300 mg base at 6h, 24h, 48h (blood stage)
2. **PLUS Primaquine** 30 mg base PO daily x 14 days (hypnozoites - prevent relapses)
   - **Check G6PD FIRST**

---

## 3. *PLASMODIUM MALARIAE*

**Treatment:**

**Same as chloroquine-sensitive *P. falciparum*:**
- **Chloroquine phosphate** 600 mg base → 300 mg base at 6h, 24h, 48h

**Key Point:** **Chloroquine ALWAYS works** for *P. malariae* (no resistance)

**NO primaquine needed** (*P. malariae* has NO hypnozoites)

---

## 4. *PLASMODIUM KNOWLESI*

**Treatment:**

**Uncomplicated:**
- **Chloroquine** (as above) OR **ACT** (artemether-lumefantrine)

**Severe (High Parasitemia):**
- **Treat as severe *P. falciparum*** (see severe malaria card)

**Key Point:** ***P. knowlesi* = treat as *P. falciparum*** if severe

---

## SPECIAL POPULATIONS

---

### **Pregnancy:**

**Safe Options:**
- **Chloroquine** (safe all trimesters)
- **Quinine + clindamycin** (safe all trimesters)
- **Artemisinin-based therapies** (safe 2nd/3rd trimester; avoid 1st trimester)
- **Atovaquone-proguanil** (limited data, avoid if possible)

**Contraindicated:**
- **Primaquine** (hemolysis risk to fetus)
- **Tafenoquine** (hemolysis risk)
- **Doxycycline** (tooth discoloration)

**Key Point:** **Primaquine contraindicated in pregnancy** (defer until after delivery + breastfeeding)

---

### **Children:**

**Safe:**
- **Chloroquine, artemether-lumefantrine, atovaquone-proguanil** (weight-based dosing)
- **Primaquine** (if G6PD normal)

**Avoid:**
- **Doxycycline** <8 years (tooth discoloration)
- **Mefloquine** <5 kg

---

### **G6PD Deficiency:**

**Can Use:**
- **Chloroquine, artemether-lumefantrine, atovaquone-proguanil, quinine**

**AVOID:**
- **Primaquine** (severe hemolysis)
- **Tafenoquine** (severe hemolysis)

**Key Point:** **G6PD testing MANDATORY** before primaquine or tafenoquine

---

## FOLLOW-UP

**Repeat Smear:**
- **Day 3** (ensure parasitemia decreasing)
- **Day 7, 14, 28** (ensure parasite clearance)

**Treatment Failure:**
- **Persistent parasitemia at Day 3** → Consider artemisinin resistance (Southeast Asia)
- **Recrudescence** (parasitemia returns within 28 days) → Treatment failure (switch regimen)
- **Relapse** (*P. vivax*/*P. ovale* - parasitemia returns after 28 days) → Primaquine failure (re-treat with primaquine)

---

## PROPHYLAXIS (For Travelers - Briefly)

**Options:**

| **Drug** | **Dosing** | **Start** | **Duration After Return** |
|----------|------------|-----------|---------------------------|
| **Atovaquone-proguanil (Malarone)** | 1 tab PO daily | 1-2 days before | 7 days |
| **Doxycycline** | 100 mg PO daily | 1-2 days before | 28 days |
| **Mefloquine (Lariam)** | 250 mg PO weekly | 1-2 weeks before | 4 weeks |
| **Chloroquine** | 500 mg salt (300 mg base) PO weekly | 1-2 weeks before | 4 weeks |

**Key Point:** **Atovaquone-proguanil (Malarone) = shortest post-travel duration** (7 days)

---

**Mnemonic: "ACT for Resistant Falciparum"**
- **A**rtemisinin-based **C**ombination **T**herapy
- **R**esistant *P. falciparum* (worldwide except Haiti, Central America west of Panama, Middle East)

**Mnemonic: "Primaquine Prevents Persistent Vivax"**
- **P**rimaquine
- **P**revents relapses (eradicates hypnozoites)
- **V**ivax and **O**vale (relapsing species)
- Check **G6PD FIRST**

**Mnemonic: "Chloroquine for CMV (Chloroquine-sensitive, Malariae, Vivax)"**
- **C**hloroquine works for:
  - **C**hloroquine-sensitive *P. falciparum* (Haiti, Central America west of Panama, Middle East)
  - ***P. M**alariae* (always chloroquine-sensitive)
  - ***P. V**ivax* (most regions chloroquine-sensitive)

**Clinical Pearls:**
- **Chloroquine-resistant *P. falciparum* = worldwide** (except Haiti, Central America west of Panama Canal, Middle East)
- **Artemether-lumefantrine (Coartem) = FDA-approved ACT** (4 tablets PO BID x 3 days with fatty food)
- **Atovaquone-proguanil (Malarone) = alternative** (4 tablets PO daily x 3 days)
- **Quinine + doxycycline = widely available** but poor tolerability (cinchonism, hypoglycemia)
- **Mefloquine AVOID** if psychiatric history (neuropsychiatric side effects)
- ***P. vivax*/*P. ovale* = need primaquine** to prevent relapses (eradicate hypnozoites)
- **G6PD testing MANDATORY before primaquine or tafenoquine** (risk of hemolysis)
- **Primaquine 30 mg base PO daily x 14 days** (or tafenoquine 300 mg PO x1)
- **Primaquine contraindicated in pregnancy** (defer until after delivery + breastfeeding)
- ***P. malariae* = chloroquine alone** (no primaquine needed, no hypnozoites)
- ***P. knowlesi* = treat as *P. falciparum*** if severe
- **Chloroquine safe in pregnancy** (all trimesters)
- **Tafenoquine = single-dose alternative to primaquine** (FDA 2018), but G6PD testing still required

**Media:** None

**Sources:** [CDC 2024 - Malaria treatment guidelines], [WHO 2023 - Guidelines for malaria], [NEJM 2024 - Malaria treatment], [Lancet Infectious Diseases 2024 - Artemisinin resistance], [FDA 2018 - Tafenoquine approval]
